Fig. 5
From: Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease
Multi-omics analysis of liver samples from the responder and non-responder groups before treatment. (A) Principal coordinate analysis plot and (B) gene set enrichment analysis (GSEA) results of the liver tissue transcriptome. (C) Heatmap of bile acid metabolism from GSEA. The hepatic levels of (D) Cyp8b1 (E, F, G) bile acids, and total bile acids. (H) Total bile acid and bile acid composition in the serum according to the response to OCA. Data are presented as mean ± standard error of mean. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 (Mann-Whitney U test)
CA, cholic acid; CDCA, chenodeoxycholic acid; MCA, muricholic acid; HCA, hyocholic acid; DCA, deoxycholic acid; T-CA, taurocholic acid; LCA, lithocholic acid; T-CDCA, tauro chenodeoxycholic acid; G-CDCA, glycochenodeoxycholic acid; NES, normalized enrichment score; FDR, false discovery rate